A non-profit organization was established to address gaps in drug and device development for small patient populations and underserved markets. The firm focuses on identifying and acquiring stalled or overlooked programs with strong underlying potential, with the goal of advancing them into clinical development, particularly in pediatric and rare disease settings.
The firm typically adds a small number of new assets each year and is open to engaging with companies globally. While upfront financial commitments are generally modest, the firm structures partnerships to include downstream value sharing, aligning incentives around successful development and commercialization.
The firm is actively seeking medical device opportunities focused on pediatric applications, particularly solutions for congenital conditions. Areas of interest include technologies that can be tailored or customized to address the unique anatomical and clinical needs of pediatric patients.
On the therapeutics side, the firm focuses on rare and orphan diseases as well as pediatric oncology. The firm prioritizes assets that are near clinical readiness or already in clinical development, including pre-IND and early clinical-stage programs.
The firm does not impose strict requirements on company or management team composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment